Toft Group Completes Executive Search for Anatrace, Inc., in Maumee, OH

Executive search firm Toft Group has placed Mr. James Schmalz as Head of Operations at Anatrace, Inc., in Maumee, OH. Prior, he served as the Operations Manager and Site Leader for VWR Chemicals, overseeing their chemical manufacturing and distribution facility. He holds an MBA from the University of Akron.

About Anatrace, Inc.

Research facilities, academic institutions, and industrial customers worldwide have trusted Anatrace for high-purity detergents, lipids, customs, and, of course, higher standards since the late 1980s. Well regarded as top performers for membrane protein structural biology, Anatrace products are chosen for their uniquely pure molecules – and the exacting chemistry behind them.

Toft Group Completes Executive Search for ClickDiagnostics in San Jose, CA

Executive search firm Toft Group has placed Mr. Ryan Schmidt as Vice President, Marketing at ClickDiagnostics in San Jose, CA. Mr. Schmidt is a sales and marketing executive specializing in the healthcare industry. He most recently served with Alere, Inc. as Vice President of Marketing, Infectious Diseases. In this role, he successfully launched the Alere™ i Point of Care molecular platform which attained market leadership.. Mr. Schmidt received his BA in Business Communications from Gustavus Adolphus College and MBA in International Business and Marketing at Marquette University.

About ClickDiagnostics

ClickDiagnostics has brought together top-notch technologists, development activists, entrepreneurs, medical professionals and public health practitioners to bring new dimension to addressing the above issues using mobile phones. It is based on the premise that as mobile phone coverage extends to all corners of the world, mobile-phone based health services will become increasingly ubiquitous for connecting different layers of the public health infrastructure and also to collect patient health data and enable remote diagnosis connecting patients to medical professionals, anywhere. Since our incorporation in May 2008, we have been implementing mobile-phone based tele-consultation services in Africa, South Asia, and the Americas, enabling patients to access quality medical treatment in areas where there is little or no access to doctors. At the same time, we have been working with health organizations, governments, and NGOs, to collect real-time health data enabling effective health interventions. With a mobile tele-consultation platform, we also added medical record analysis features enabling doctors to view patient medical history in order to provide appropriate diagnosis and treatment advice.

Toft Group Completes Executive Search for Retrophin (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Andrea Loewen-Rodriguez as Vice President, Regulatory Affairs and Quality Assurance at Retrophin in San Diego, CA. Ms. Loewen-Rodriguez is a global regulatory executive with 20+ years of pharmaceutical industry experience. She previously served at Vital Therapies as Vice President, Regulatory Affairs/ Quality where she was appointed to manage development and execution of U.S., EU, and RoW regulatory strategies. Prior to her role at Vital, Ms. Loewen-Rodriguez served at Shire Pharmaceuticals as Senior Director- Head, Global Regulatory Affairs- Regenerative Medicine. She earned her BA in Biology from Gustavus Adolphus College.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.

Toft Group Completes Executive Search for Retrophin (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Gayle Bresnahan as Associate Director, Clinical Operations at Retrophin in San Diego, CA. Ms. Bresnahan offers 20 years of clinical research within Oncology, Diabetes, Nephrology, Neurology and Infectious Disease therapeutic areas. She most recently served at Intercept Pharmaceuticals as Associate Director, Clinical Operations, where she was responsible for project management and execution of Phase II and III non-viral liver disease studies. Ms. Bresnahan received her BS in Business Administration from Bristol University.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.

Toft Group Completes Executive Search for Ascendis Pharma Inc., (NASDAQ: ASND) in Palo Alto, CA

Executive search firm Toft Group has placed Dr. Aimee Shu as the Director, Clinical Development Endocrinology for Ascendis Pharma in Palo Alto, CA. Dr. Shu is a board-certified Endocrinologist who joins Ascendis from Stanford University where she served as Clinical Associate Professor of Medicine and Associate Program Director, Endocrinology Fellowship Training Program. She earned her MD from Harvard Medical School.

About Ascendis Pharma

Ascendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.

Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia. Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.

Robin Toft, CEO of Toft Group Executive Search, 5-Time Finalist for Most Admired CEO Award

San Diego, CA – Toft Group, a top executive recruiting firm focusing exclusively on building leadership teams for Life Sciences and Healthcare companies, is proud to announce that President & CEO, Robin Toft, was named a finalist for the 2017 Most Admired CEO Award, in the category of Private Company by the San Diego Business Journal.

This presigious award recognizes San Diego business leaders’ significant achievements in innovation, financial success, philanthropic involvement, and employee empowerment within their companies and in the community. Nominees are judged in the categories of nonprofit organization, business nonprofit, education, family-owned business, government agency, privately held company and public company.

This is the 5th ‘Most Admired CEO’ finalist award for Toft, who was also recognized by the San Diego Business Journal as a “Women Who Mean Business” finalist two consecutive years. Mr. J. David Enloe, whom Toft Group placed as CEO of Ajinomoto Althea, Inc. won the award for the Private Company category that included over 200 employers.

“I am honored to be alongside such exceptional an incredible group of leaders in San Diego who are continuously improving our local economy,” commented Toft. “We are thrilled one of the executives in Toft Group’s network, David Enloe, was awarded and extend our congratulations to the outstanding recipients for their well-deserved awards.”

All finalists were recognized at a special ceremony on Thursday June 15th, 2017.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. Named a Top 150 Fastest Growing Private Company and a Top 50 Executive Search Firm in Life Sciences, we are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations. For more information, visit www.thetoftgroup.com.

Toft Group Completes Executive Search for Greenwich Biosciences (NASDAQ: GWPH) in Carlsbad, CA

Executive search firm Toft Group has placed Mr. Jeff Krol as Vice President, Market Access at Greenwich Biosciences in Carlsbad, CA. Mr. Krol brings 25 years of experience in managed markets leadership. He most recently served with Avanir Pharmaceuticals as Executive Director, Managed Markets and Project Management, and previously served in the same company as Senior Director, Managed Markets. Mr. Krol earned his B.S. in Chemistry and Physics from The Ohio State University, and his M.S. in Education from the University of California, Berkeley.

About Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy.

Toft Group Completes Executive Search for Muse Bioscience in Boulder, CO

Executive search firm Toft Group has placed Mr. Jason Amsbaugh as Senior Director, Marketing at Muse Bioscience in Boulder, CO. Mr. Amsbaugh brings over a decade of experience in marketing and product management in the industry to this new role. He most recently served as the Director of Global Marketing for ArcherDX, a NGS-based cancer diagnostic startup. Prior, he served with Thermo Fisher Scientific as a Product Portfolio Manager and early in his career held sales roles for industry leaders Abbott Molecular Diagnostics, Thermo Fisher Scientific, and VWR International. Mr. Amsbaugh earned his MBA from the University of Colorado, Boulder and BS degree from Colorado State University.

About Muse Bioscience

Muse bio is inspiring a new era of genome engineering that will transform our understanding of biology. Muse bio delivers power to researchers and production scientists in the field of genome engineering and synthetic biology through the combination of a powerful forward design software package, a proprietary benchtop biofoundry, and custom consumables and reagents. Its next-generation, CRISPR-based ForgeCraft technology dramatically improves and simplifies genome engineering.

Toft Group Completes Executive Search for Drawbridge Health in Menlo Park, CA

Executive search firm Toft Group has placed Mr. Lee McCracken as Chief Executive Officer at Drawbridge Health in Menlo Park, CA. Mr. McCracken is a C-level executive with over 20 years of pharmaceutical, biotech, diagnostics, and venture capital experience. He previously served as the Chief Executive Officer of Gensignia Life Sciences Inc., a privately held miRNA-digital IT company, where he was charged with developing strategy, establishing a clinical laboratory, and performing clinical studies for reimbursement. Prior to his role at Gensignia, Mr. McCracken was the President and Chief Executive Officer of Pathwork Diagnostics, Inc.. Mr. McCracken earned his B.S. in Commerce from Santa Clara University, his M.S. in Computer Science from the University of Dayton, and an MBA in Strategy/Venture Capital from the University of California, Los Angeles

About Drawbridge Health

Drawbridge Health is a medical technology company fusing the science of chemistry with the fundamentals of logistics to greatly improve the blood sampling process. Our mission is to power the shift in healthcare from being reactive to proactive, enabling predictive medicine to be realized by bridging diagnostic testing from sample to delivery to decision. This transformation begins with how we approach the collection and the interpretation of medical diagnostics tests – the data that we use to make nearly all of our medical decisions.

Toft Group Completes Executive Search for First Light Biosciences in Bedford, MA

Executive search firm Toft Group has placed Mr. Kevin Wyckoff as Vice President, Regulatory & Clinical Affairs in Bedford, MA. Mr. Wyckoff brings 25 years of diverse management experience to First Light in quality assurance and regulatory affairs. He most recently served with Roka Bioscience, a molecular diagnostics company, as the VP, Quality, Regulatory and Compliance, and previously served as the Director of Regulatory Affairs for Ortho Clinical Diagnostics. Mr. Wyckoff earned his B.S. in Chemistry from Louisiana State University, and his M.S. in Regulatory Sciences from Northeastern University.

About First Light Biosciences

First Light Biosciences is developing breakthrough automated medical diagnostic products for rapid, sensitive, and cost-effective detection of Healthcare Associated Infections (HAI). The products address the need for cost-effective and accurate diagnostics to meet the explosive growth in testing. New testing is being driven by clinical studies showing that testing for the infectious agents can help to dramatically lower the rate of hospital infections. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the performance of the most advanced commercial laboratory tests with unprecedented affordability and ease-of-use.